NCT03364231 2023-06-23Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's LymphomaTG Therapeutics, Inc.Phase 2 Completed21 enrolled 14 charts